Grillot D, Pessi A, Verdini A S, Lambert P H, Del Giudice G
Department of Pathology, University of Geneva, Switzerland.
Med Microbiol Immunol. 1990;179(5):237-44. doi: 10.1007/BF00192461.
The immunogenicity of the carrier-free synthetic peptide, (NANP)40, from the repetitive region of the Plasmodium falciparum circumsporozoite (CS) protein was investigated in genetically responder mice (C57BL/6, H-2b) acutely infected with blood forms of the non-lethal murine malaria parasite, P. yoelii. As compared to non-infected mice, P. yoelii-infected C57BL/6 mice produced significantly lower titers of anti-(NANP)40 IgG antibodies. This decrease in the anti-(NANP)40 antibody response peaked with the peak of parasitemia, and involved all the IgG subclasses. Interestingly, this P. yoelii-mediated effect was evident both on the development of the antibody response to the (NANP)40 peptide, and on an already established anti-(NANP)40 antibody titer, as seen in mice immunized with the peptide 1 month before the infection. Since (NANP)n-based constructs are strongly envisaged as potential vaccines against falciparum malaria, these results might be important in the evaluation of the efficacy of these vaccine candidates, when they will be used in individuals living in endemic areas.
在急性感染非致死性鼠疟原虫约氏疟原虫血液期的基因反应型小鼠(C57BL/6,H-2b)中,研究了来自恶性疟原虫环子孢子(CS)蛋白重复区域的无载体合成肽(NANP)40的免疫原性。与未感染小鼠相比,感染约氏疟原虫的C57BL/6小鼠产生的抗(NANP)40 IgG抗体滴度显著降低。抗(NANP)40抗体反应的这种降低在寄生虫血症高峰期达到峰值,并且涉及所有IgG亚类。有趣的是,约氏疟原虫介导的这种效应在对(NANP)40肽的抗体反应的发展以及已建立的抗(NANP)40抗体滴度上均很明显,如在感染前1个月用该肽免疫的小鼠中所见。由于基于(NANP)n的构建体被强烈设想为抗恶性疟的潜在疫苗,当这些候选疫苗用于流行地区的个体时,这些结果可能对评估其效力很重要。